Nasdaq:US$14.54 (-0.06) | HKEX:HK$22.50 (-0.15) | AIM:£2.17 (-0.04)
News & Presentations
Previous Article   |   Next Article
Presentations | 22 Jan 2022

ASCO GI 2022 | Phase 1/1b trial of fruquintinib in patients with advanced solid tumors: preliminary results of the dose expansion cohorts in refractory metastatic colorectal cancer